AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Achiko AG

Report Publication Announcement Jul 7, 2022

804_iss_2022-07-07_8da64ffb-29db-4411-b1d6-de86f9a37698.html

Report Publication Announcement

Open in Viewer

Opens in native device viewer

Achiko AG / Key word(s): Miscellaneous

Achiko AG – Investor Briefing

07.07.2022 / 19:45


Achiko AG – Investor Briefing

Zurich, 7 J u ly 2022:  Achiko AG (SIX: ACHI; OTCQB: ACHKF; ISIN CH0522213468) (“Achiko”, the “Company”), would like to invite investors and shareholders to a moderated investor call. A powerpoint presentation will be available around the time of the call and published on the website.

Details are as follows:

Date:  8 July 2022

Time:  2.30pm CEST / 8.30am EDT

Format:  Zoom Call

Presenter: Mr Steven Goh, CEO of Achiko AG

Meeting link: https://us02web.zoom.us/j/6191486127?pwd=VWJYa0VmWFV3OTBiL1RDd0o5NjR2dz09

Meeting ID: 619 148 6127

Passcode: 888

Find your local number: https://us02web.zoom.us/u/knHHcenwR

ABOUT ACHIKO A G  

Achiko AG (SIX: ACHI.SW; OTCQB: ACHKF; ww w.achiko.com ) is developing disruptive diagnostic solutions that puts people first. The company’s lead product is a rapid, reliable Covid-19 test with a companion app offering a user-friendly digital health passport. The test and companion app were launched in Indonesia in mid-2021 and an application for CE Mark approval in Europe will be submitted in 2022.  

Achiko creates and develops aptamer-based diagnostics through its biotechnology division, AptameX TM and companion health apps via its digital mobile health technology division, Teman Sehat TM . The AptameX DNA aptamer tests can be rapidly chemically synthesised, are cost-effective and have wide potential across multiple disease diagnostics. Leveraging AptameX and Teman Sehat, Achiko aims to deliver fast, accurate and affordable diagnostic testing for a range of pathogenic diseases and therapeutic indications in the rapidly evolving healthcare diagnostics field.  

Headquartered in Zurich, Achiko has offices in Jakarta, and staff around the world. 

M edia contacts:   

ACHIKO A G  

Investor Relations 

E:  [email protected] 

Switzer l and & G lo b al  

Marcus Balogh 

Farner Consulting Ltd. 

E:  [email protected] 

T: +41 44 266 67 67 

Disclaimer  

T his communi c a tio n expressl y or i m plicitly c o nta i ns certa i n f or w ard-look i ng s tatem e nts c o ncernin g A chik o A G an d it s business . Suc h stat e ment s in v olv e certai n k n o w n a n d un k no w n risks, uncer t ainties a n d othe r f actors, w hi c h coul d cause the actua l results, f i n ancial c o nditi o n, per f or m ance or achi e vement s o f A chik o A G to be material l y di ff erent f rom any f u t ure results, pe r f ormance or achiev e ments expressed or implie d by such f or w ard-l o oki n g statem e nts. A chiko A G is providing this com m uni c ati o n as o f this date and d oe s not u nder t ake to u p d ate a n y f or w ard- l ooki n g stat e ments contain e d herein as a result o f ne w in f ormat i on ,   f uture eve n ts or o ther w ise.  


End of Media Release


Language: English
Company: Achiko AG
Tessinerplatz 7
8002 Zurich
Switzerland
E-mail: [email protected]
Internet: https://www.achiko.com/
ISIN: CH0522213468
Valor: 48788430
Listed: SIX Swiss Exchange
EQS News ID: 1393507
End of News EQS News Service

1393507  07.07.2022

Talk to a Data Expert

Have a question? We'll get back to you promptly.